Critical Review: Phio Pharmaceuticals (NASDAQ:PHIO) & Aurinia Pharmaceuticals (NASDAQ:AUPH)

Phio Pharmaceuticals (NASDAQ:PHIO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Phio Pharmaceuticals and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-66.59%	-60.26%
Aurinia Pharmaceuticals	101.46%	27.47%	19.61%

Analyst Ratings

This is a summary of current ratings for Phio Pharmaceuticals and Aurinia Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1	0	1	0	2.00
Aurinia Pharmaceuticals	0	4	2	0	2.33

Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 1,057.02%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 9.45%. Given Phio Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Institutional and Insider Ownership

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Valuation and Earnings

This table compares Phio Pharmaceuticals and Aurinia Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70 million	($1.45)	-0.83
Aurinia Pharmaceuticals	$283.06 million	7.40	$287.20 million	$2.08	7.58

Aurinia Pharmaceuticals has higher revenue and earnings than Phio Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Aurinia Pharmaceuticals beats Phio Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.